<DOC>
	<DOCNO>NCT00955240</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill tumor cell . Drugs use chemotherapy , fluorouracil cisplatin , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Giving radiation therapy together combination chemotherapy cetuximab may kill tumor cell . PURPOSE : This phase II trial study give radiation therapy together cisplatin , fluorouracil , cetuximab see well work treat patient locally advanced anal cancer .</brief_summary>
	<brief_title>Radiation Therapy , Cisplatin , Fluorouracil , Cetuximab Treating Patients With Locally Advanced Anal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate objective response ( complete partial ) 8 week completion study treatment comprise radiotherapy , chemotherapy ( fluorouracil cisplatin ) , cetuximab follow additional radiotherapy patient locally advanced anal cancer . Secondary - Evaluate colostomy-free survival . - Evaluate local control rate ( objective response stabilization ) 8 week . - Evaluate relapse-free survival 5 year . - Evaluate intermediate objective response end week 5 radiotherapy . - Evaluate overall survival 5 year . - Evaluate duration response . - Evaluate acute toxicity accord CTCAE v3.0 . - Evaluate late toxicity 5 year accord CTCAE v3.0 . - Study tumor marker associate response ( survival without relapse ) toxicity . - Study genotypes Fc-receptor immunoglobulin ( FCGR2A FCGR3 ) association skin toxicity , objective survival , relapse-free survival . OUTLINE : This multicenter study . Patients receive cetuximab IV day 0 , 7 , 14 , 21 , 28 , 35 ; fluorouracil IV day 7-10 35-38 ; cisplatin IV 2 hour day 7 35 . Beginning day 7 , patient also undergo radiotherapy 5 day week 5 week ( week 2-6 ) . Two week finish treatment , patient undergo additional radiotherapy* 5 day week 2 week ( week 9 10 ) . NOTE : *Some patient may undergo brachytherapy . Blood tissue sample collect analysis . After completion study treatment , patient follow 4 year .</detailed_description>
	<mesh_term>Anus Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm anal cancer Squamous cell disease Locally advance , nonmetastatic disease One follow clinical TNM stage : T2 , N0 , M0 ( large diameter ≥ 3 cm ) T3T4 , N0 , M0 Any T , N1N3 , M0 No undifferentiated small cell carcinoma adenocarcinoma Measurable disease accord RECIST criterion Undergone endorectal ultrasound MRI evaluate primary tumor Undergone thoracoabdominopelvic scan evaluate tumor extension Disease suitable receive radiotherapy chemotherapy PATIENT CHARACTERISTICS : ECOG performance status 01 Leukocytes ≥ 4,000/mm^3 ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10 g/dL Creatinine clearance &gt; 60 mL/min ALT AST ≤ 5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2.5 time ULN Total bilirubin ≤ 1.5 time ULN Not pregnant nursing Negative pregnancy test No history cancer within past 8 year except situ cervical cancer previously treat basal cell carcinoma skin No contraindication component study therapy No serious uncontrolled illness No symptomatic grade 1 angina pectoris angina pectoris ≥ grade 2 No congestive heart failure No peripheral sensory neuropathy No uncontrolled diabetes No HIV positivity No geographical , social , psychological situation preclude medical follow Affiliated social security system No patient deprive liberty trusteeship PRIOR CONCURRENT THERAPY : Patients divert colostomy eligible No prior excision tumor No prior chemotherapy radiotherapy treatment cancer history radiotherapy pelvic brachytherapy No concurrent coumarin anticoagulant , phenytoin , sorivudine brivudine , antacid , allopurinol Not register another clinical trial experimental drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>stage II anal cancer</keyword>
	<keyword>stage IIIA anal cancer</keyword>
	<keyword>stage IIIB anal cancer</keyword>
	<keyword>squamous cell carcinoma anus</keyword>
</DOC>